Literature DB >> 19229850

CD247 can bind SHC1, no matter if CD247 is phosphorylated.

Tao Liu1, Fangjin Chen, Ning Tang, Jiannan Feng, Dongsheng Zhao, Kaihua Wei, Yunping Zhu, Fuchu He, Shaojun Liu.   

Abstract

On T cell receptor (TCR) stimulation, src homology 2 domain-containing transforming protein C1 (SHC1) had been found to bind the tyrosine-phosphorylated CD247 chain of the receptor via its src homology 2 (SH2) domain, delivering signals that control T cell development and activation. However, how the phosphorylation of CD247 led to the instant binding has not been characterized clearly. To study the binding process in detail, we simulated and compared the interaction processes of the SH2 domain with CD247 and phosphorylated CD247, respectively. Unexpectedly, the simulation revealed that SHC1 can also bind the nonphosphorylated CD247 peptide, which was further validated to be a weak binding by affinity pull-down experiment. The molecular dynamics (MD) simulation also revealed that the CD247 peptide formed a folding conformation with its Leu209 inserted into the hydrophobic binding pocket in SHC1. And on phosphorylation, it was the electrostatic attraction between the CD247 Tyr(P)206 and the SHC1 Tyr(P)-binding pocket that destroyed the folding conformation of the nonphosphorylated CD247 and, aided by the electrostatic attraction between SHC1 and the Asp203 of CD247, led to the extended conformation of the phosphorylated CD247 binding to SHC1 strongly. The results suggest that nonphosphorylated CD247 can recruit SHC1 in advance to prepare for the instant needs for SHC1 on TCR stimulation. In view of the ubiquity of phosphorylation in protein interaction regulation, we think this study also exemplified the usefulness of MD in more interactome research involving phosphorylation. Copyright 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229850     DOI: 10.1002/jmr.933

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  1 in total

1.  PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.

Authors:  Jian-Ming Xu; Yan Wang; You-Liang Wang; Yan Wang; Tao Liu; Ming Ni; Man-Sheng Li; Li Lin; Fei-Jiao Ge; Chun Gong; Jun-Yan Gu; Ru Jia; He-Fei Wang; Yu-Ling Chen; Rong-Rui Liu; Chuan-Hua Zhao; Zhao-Li Tan; Yang Jin; Yun-Ping Zhu; Shuji Ogino; Zhi-Rong Qian
Journal:  Clin Cancer Res       Date:  2017-04-19       Impact factor: 12.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.